Novartis Unveils New Strategy Based On Eight Multibillion- Dollar Brands

Novartis Unveils New Strategy Based On Eight Multibillion- Dollar Brands

ZURICH (Reuters) -Novartis unveiled a new strategy on Thursday based on eight big drug brands as the pharmaceuticals maker reshapes itself following the decision to spin off its underperforming generics business Sandoz. Ahead of an investor event, the Swiss company said the currently in-market brands – Cosentyx, Entresto, Zolgensma, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix…

Read More